마우스에서 우측 관상동맥의 영구적 결찰에 의해 유도되는 우심실 심근경색의 생성 및 특성화

Executive Industry Relevance

Robust preclinical models of right ventricular infarction (RVI) are essential for elucidating mechanisms of right heart failure and for identifying therapeutic targets relevant to human disease. This protocol enables reproducible generation and quantitative characterization of RVI in mice, supporting translational research and mechanistic de-risking at early discovery and preclinical stages. The model's quantitative outputs facilitate predictive confidence and portfolio triage for cardiovascular drug discovery programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of right ventricular injury mechanisms and remodeling pathways.
• Supports functional target validation for right heart failure interventions.
• Provides a platform for mechanistic de-risking of candidate targets in a disease-relevant system.
• Facilitates predictive confidence in translational hypotheses for right ventricular pathology.

Screening & Assay Development

• Delivers validated in vivo endpoints including infarct size, echocardiographic parameters, and hemodynamic measurements.
• Supports assay standardization and reproducibility for cross-study comparisons.
• Enables quantitative assessment of compound efficacy in a physiologically relevant context.
• Prepares the system for downstream screening of therapeutic candidates targeting RV remodeling.

Translational & Preclinical Research

• Aligns preclinical endpoints with clinical measures of RV function and remodeling.
• Provides continuity from mechanistic discovery to preclinical validation of therapeutic strategies.
• Supports risk-adjusted advancement decisions based on quantitative translational biomarkers.
• Facilitates evaluation of disease-modifying effects in a model mimicking patient pathophysiology.

Pipeline & Workflow Integration

This RVI model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies with translational validation for right heart failure programs.

• Discovery Biology: Supports hypothesis testing and pathway clarification for RV injury and remodeling.
• Screening: Provides reproducible, quantitative outputs for compound evaluation and assay development.
• Analytics: Enables measurement of infarct size, cardiac function, and hemodynamics for comparative analysis.
• Translational Research: Aligns preclinical findings with clinical endpoints relevant to RV dysfunction.
• Enterprise Reuse: Establishes a reusable in vivo platform for ongoing cardiovascular R&D initiatives.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in right heart failure research.
• Operational Value: Standardizes model generation and quantitative assessment for reproducibility and scalability.
• Strategic Value: Informs go/no-go decisions and enhances capital efficiency by enabling early de-risking.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of cardiovascular assets targeting RV pathology.

Implementation Considerations

• Requires expertise in microsurgical techniques and small animal anesthesia.
• Demands access to echocardiography, hemodynamic monitoring, and histological analysis infrastructure.
• Necessitates cross-team standardization of procedural steps and data interpretation.
• Adaptation may be needed for different mouse strains or comorbid models.
• Success and survival rates depend on precise ligation and perioperative management.

Biopharma FAQs